Leritrelvir for the treatment of mild or moderate COVID-19 without co-administered ritonavir: a multicentre randomised, double-blind, placebo-controlled phase 3 trialResearch in context

Summary: Background: Leritrelvir is a novel α-ketoamide based peptidomimetic inhibitor of SARS-CoV-2 main protease. A preclinical study has demonstrated leritrelvir poses similar antiviral activities towards different SARS-CoV-2 variants compared with nirmatrelvir. A phase 2 clinical trial has show...

Повний опис

Бібліографічні деталі

Автори:	Yangqing Zhan, Zhengshi Lin, Jingyi Liang, Ruilin Sun, Yueping Li, Bingliang Lin, Fangqi Ge, Ling Lin, Hongzhou Lu, Liang Su, Tianxin Xiang, Hongqiu Pan, Chaolin Huang, Ying Deng, Furong Wang, Ruhong Xu, Dexiong Chen, Ping Zhang, Jianlin Tong, Xifu Wang, Qingwei Meng, Zhigang Zheng, Shuqiang Ou, Xiaoyun Guo, Herui Yao, Tao Yu, Weiyang Li, Yu Zhang, Mei Jiang, Zhonghao Fang, Yudi Song, Ruifeng Chen, Jincan Luo, Changyuan Kang, Shiwei Liang, Haijun Li, Jingping Zheng, Nanshan Zhong, Zifeng Yang, Huang Yanming, M.M, Dong Haiping, M.D., Jinlin Hou, M.M, Shao Lei, M.D., Li Xiaoguang, M.D., Gao Yan, M.M.
Формат:	Artigo
Мова:	Inglês
Опубліковано:	Elsevier 2024-01-01
Серія:	EClinicalMedicine
Предмети:	Anti SARS-CoV-2 drug Mono-therapy COVID-19 Drug-drug interaction RCT
Онлайн доступ:	http://www.sciencedirect.com/science/article/pii/S2589537023005369
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!